Oral formulation for novel inhibitor of RAS driven cancers
Ended Project Grant Awarded Last action
- Award ID
- R43CA217502
- Recipient
-
ADT Pharmaceuticals, LLC UEI YL5LNM35E194
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $301,330
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date
- Originally
- Place of performance
- Orange Beach, AL 36561, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | -$670 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $2,000 | |
| Original award | $300,000 |
Quick answers
Who received award R43CA217502?
R43CA217502 was awarded to ADT Pharmaceuticals, LLC by National Cancer Institute (National Institutes of Health) on September 21, 2017.
How much is award R43CA217502 worth?
$301,330 has been obligated on R43CA217502.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award